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Abstract
Purpose Radial scar’s stellate appearance may mimic carcinoma mammographically and histologically. Management of
radial scar (RS) found on breast core needle biopsies (CNB) ranges from excision to clinical observation due to the variation
in reported upgrades to malignancy at surgical excision. We examined the upgrade rate in patients with RS detected on CNB
at our institution and reviewed the current literature.
Methods A retrospective study was conducted of all cases with RS diagnosed on CNB between December 2006 and March
2017 at our institution. Inclusion criteria were patients with “pure” RS and RS associated with high-risk lesions (HRL).
Upgrade was defined as invasive or non-invasive cancer in the excisional biopsy.
Results 157 cases were identified with RS on CNB, and 122 cases met inclusion criteria. Of these 122 cases, 91 (75%) had
pure RS on CNB while 31 (25%) had associated atypia or HRL. 81 (66%) of patients proceeded to excisional biopsy and
41 (34%) did not. Two patients (1.6% of total) were found to have a low-grade invasive ductal carcinoma (0.6 and 0.8 cm)
upon surgical excision. None of the remaining 120 patients developed an ipsilateral breast cancer with a mean of 32.3-month
follow-up.
Conclusions We found a very low upgrade rate to breast cancer when RS was found on CNB with or without associated
HRL. Our results are consistent with other reported series. Our data do not support surgical excision for RS but rather close
clinical follow-up for patients with RS on CNB.
Keywords Breast cancer · Radial scar · Core needle biopsy
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Radial scars (RS) are entities which are described mammographically and pathologically. They are benign breast
lesions that are commonly detected by pathologists [1]. The
risk of subsequent breast cancer associated with RS found
on pathology with and without atypia ranges from 1.1–3.0 to
2.8–6.7% respectively [2]. Patients with RS in benign breast
biopsies were found to have twice as great risk of subsequent
breast cancer [1, 3].
Radiographically, RS are characterized by an area of
architectural distortion with a central radiolucency and the
presence of radiating spicules. RS, detected on breast pathological specimens, are benign lesions and are part of the
sclerosing adenosis spectrum. Histologically, RS are characterized by a central fibroelastic core containing entrapped
glandular elements and ducts that radiate outward giving the
lesion a characteristic stellate appearance. Histologic and
radiographic RS do not have an exact correspondence [4–6]
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and the majority of pathological RS are found incidentally
at biopsy for unrelated mammography findings. Because of
the reported association of RS with surrounding proliferative
disease and malignancy, excisional biopsy of RS detected on
core needle biopsy (CNB) has been advocated [7–9].
Several histological diagnoses found at image-guided
CNB of breast lesions have been shown to be associated with
a sampling error rate that is high enough to warrant surgical excision. RS found on CNB from image-guided biopsies
may be a microscopic incidental finding, may account for
the imaging findings, or may be a high-risk lesion warranting surgical excision. Several retrospective reviews of surgical specimens obtained after RS diagnosis on CNB have
reported an increased incidence of associated proliferative
disease, malignancy, or both [7, 9–15]. Some studies have
reported malignancy rates associated with RS with surgical
excision as high as 29–30% [9, 16, 17]. Based on the association of RS with other proliferative or malignant processes
or the possibility of sampling error, surgical excision has
become the standard of care to avoid missing a low-grade
cancer or upgrading to a high-risk lesion.
Given the improvement in imaging, biopsy devices, and
pathological examination, we examined the outcome of
patients with RS detected on CNB at our institution as well
as reviewed the current literature.

Methods
This retrospective study was reviewed and approved by the
Institutional Review Board of Washington University School
of Medicine. The Barnes-Jewish Hospital pathology database was searched for the terms “RS” and “RS core” from
December 2006 to March 2017. Inclusion criteria included
patients with “pure” RS and RS associated with high-risk
lesions (HRL). Both imaging-targeted lesions and incidental
pathologic findings of RS were included. Exclusion criteria
were RS associated with malignancy at percutaneous biopsy,
patients with simultaneous or previous ipsilateral breast cancer diagnosis within 6 months prior to CNB, patients who
were lost to follow up as defined by last follow-up date corresponding to the date of the CNB, and patients who were
never physically seen at our medical center, though their
pathology was reviewed at our institution. Follow-up was
defined as the time interval from the CNB to the date of the
last recorded visit to our institution.
All mammograms were interpreted and biopsies recommended by a core of five radiologists who are dedicated
fellowship trained mammographers. All pathology results
were interpreted by dedicated breast pathologists. Each
CNB was recorded for its modality [stereotactic, ultrasound (US), or MRI-guided], mammographic finding, and
excisional pathology when performed. Ipsilateral atypia or
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carcinoma in the same core biopsy was also recorded. Highrisk lesions (HRL) included atypical ductal hyperplasia
(ADH), lobular carcinoma in situ (LCIS), atypical lobular
hyperplasia (ALH), and papilloma. In cases where there was
more than one HRL in the biopsy, the higher ranked HRL
was recorded. For our study, an upgrade from the CNB was
defined as upgrade to an invasive or non-invasive breast cancer on the excisional pathology report. Benign lesions were
defined as any lesion that did not require further clinical
treatment.

Statistical method
Tests for statistical significance of the association between
demographic/clinicopathologic factors and pathologic
upgrade were performed using the Chi square (χ2) test. Statistical significance was defined to be P < 0.05.

Results
RS was identified on 157 image-guided CNB. 35 cases
were excluded from this study due to simultaneous ipsilateral breast cancer, lost to follow up, or never seen at our
medical center (Supplemental Table 1). Of the remaining
122 patients, approximately one-third of the women were
between the ages of 50 and 69. Approximately 80% were
Caucasian and 20% minority, reflective of the population
served by the medical center. The most common mammographic findings for biopsy recommendation were architectural distortions (27%), mass (22%), and calcifications
(19%). Mammographic mass diameter measured from the
mammographic or US views ranged from 0.3 to 3.5 cm
(mean 0.9 cm). The most common types of diagnostic
biopsies performed were stereotactic core vacuum-assisted
biopsy (VAB) with 9-gauge needles (67%), followed by USguided biopsy with 14-gauge needles (24%) and MRI-guided
biopsy with 9-gauge needles (9%) (Table 1).
81 (66%) of 122 patients underwent a surgical excision
of the RS area and 41 (34%) did not. Seven of the patients
(17%) who did not undergo an excision were diagnosed with
a concurrent contralateral breast cancer and the RS was diagnosed during their work-up. The mean age of those undergoing excision was 64 versus 58 for those who did have further
surgery and this was significant (P = 0.02). Otherwise, there
was no significant difference in race, mammographic indication for core biopsy, type of core biopsy, and biopsy needle
gauge between those patients who had an excision versus
those who did not. There were a slightly higher percentage
of African-American women who did not undergo surgical
excision compared to African-American women who underwent surgery (19 vs. 5% respectively) (Table 1).
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Table 1  Demographics and clinicopathologic features of 122 patients with RS on breast core biopsy
Characteristic
Age—n (%)
< 39
40–49
50–59
60–69
70–79
> 80
Age—mean (SD)
Race/ethnicity—n (%)
White
Hispanic
Asian
African-American
Other
Unknown
Indication for core biopsy—n (%)
Architectural distortions
Architectural distortions + calcifications
Architectural distortions + mass
Architectural distortions + focal asymmetry
Mass
Mass + calcifications
Asymmetrical density
Focal asymmetry
Focal asymmetry + mass
Calcifications/microcalcifications
Non-mass like enhancement
Type of core biopsy—n (%)
Stereotactic
Ultrasound
MRI-guided
Biopsy needle gauge (G)—n (%)
9 G-vacuum assisted
14 G-spring assisted

Patients who underwent surgical
excision, n = 81 (%)

Patients who did not undergo surgical
excision, n = 41 (%)

4 (5)
15 (19)
30 (37)
22 (27)
8 (10)
2 (2)
58 (10)

0 (0)
6 (15)
7 (17)
13 (32)
12 (29)
3 (7)
64 (12)

71 (88)
0 (0)
2 (2)
4 (5)
2 (2)
2 (2)

32 (78)
0 (0)
1 (2)
8 (20)
0 (0)
0 (0)

26 (32)
10 (12)
8 (10)
0 (0)
17 (21)
0 (0)
1 (1)
4 (5)
1 (1)
12 (15)
2 (2)

7 (17)
3 (7)
1 (2)
1 (2)
10 (24)
2 (5)
0 (0)
4 (10)
0 (0)
12 (29)
1 (2)

52 (64)
22 (27)
7 (9)

30 (73)
7 (17)
4 (10)

74 (91)
7 (9)

37 (90)
4 (10)

P value
0.02*

0.09

0.10

0.47

0.84

*Statistically significant P < 0.05

RS with atypia on core biopsy
Of the 122 core pathologies reviewed, 91 (75%) were
not associated with atypia and 31 (25%) were associated
with atypia, including ADH, ALH/LCIS, and papilloma
(Table 2). Of the 31 patients with RS and atypia on imageguided CNB, 26 (84%) of the patients had an excisional
biopsy and none of these patients were diagnosed with a
breast cancer on the excisional biopsy (Fig. 1). None of the
five patients who did not have an excisional biopsy (all with
RS/papilloma on CNB) were later diagnosed with an ipsilateral breast cancer with a mean follow-up of 75.0 months

Table 2  Core needle biopsy pathology (n = 122)
Core biopsy results

n (%)

“Pure” radial scar
Radial scar with ADH
Radial scar with lobular neoplasia
Radial scar with papilloma

91 (75)
9 (7)
8 (7)
14 (11)
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RS Core Biopsies (122)

No Atypia on Core (91)

No excision (36a)

Atypia on Core (31)

Excision (26)

No excision (5)

Excision (55)
Benign (53b)

Benign (26a)

IBC (2)
DCIS (0)

IBC (0)
DCIS (0)

Fig. 1  Outcome of patients diagnosed with RS on CNB (number). Number of cases with contralateral breast cancer: a7 cases, b4 cases

Table 3  Surgical pathology of radial scars (n = 81)
Biopsy pathology

n (%)

Surgical pathology

“Pure” radial scar
Radial scar with ADH
Radial scar with lobular neoplasia
Radial scar with papilloma

55 (68)
9 (11)
8 (10)
9 (11)

2 IDC
All benign
All benign
All benign

0.1–101.2 months). Of the 55 patients without atypia who
did undergo surgical excision, 53 (96%) of the pathologies
were benign and 2 cases yielded small invasive cancers.
Both cancers were invasive ductal carcinoma (IDC), grade
1, estrogen receptor-positive/Her2-negative and were 0.6 and
0.8 cm, respectively (Table 4).

Contralateral breast cancer

(range 0.4–111.6 months) nor were any of the patients
who had an excisional biopsy diagnosed with an ipsilateral
breast cancer with a mean follow-up of 23.4 months (range
0.5–94.0 months) (Table 3).

Pure radical scar
Of those 91 patients with RS only on core biopsy, 55 (60%)
underwent an excisional biopsy and 36 (40%) did not
(Fig. 1). Of those 36 patients who did not undergo an excisional biopsy, none of the patients developed an ipsilateral
breast cancer with a mean follow-up of 42.9 months (range

In our study, 18 patients had concurrent contralateral breast
cancer. Of these patients, 11 had pure RS found on CNB,
while 7 had associated atypia on CNB. Patients with associated atypia on CNB all underwent surgical excision and all
of the pathologies were benign. Of the patients with pure RS
found on CNB, 4 underwent excision with resultant benign
pathology, while 7 underwent imaging follow-up (mean
49.3 months, range 0.7–101.2 months). The mean followup for this group was 39.9 months, and none of the patients
developed an ipsilateral breast cancer. All received appropriate treatment for their contralateral breast cancer.

Table 4  Cancer upgrade cases after surgical excision
Patient age Image type

Indication for biopsy RS pathology Biopsy method

Biopsy
needle
gauge

59

Mammogram Architectural distortion, mass (8 mm)

RS

63

Mammogram Mass (7 mm)

RS fragments US-guided spring assisted 14 G

13

US-guided spring assisted 14 G

Cancer type

ER/PR/Her2

IDC, grade 1, 6 mm ER+/
PR+/
Her2−
IDC, grade 1,
ER+/
8 mm
PR+/
Her2−
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Literature review
We reviewed 16 studies (including our data) published
from 2014 to 2018 with chart reviews from 1994 to 2017
(Table 5). For each study, the number of excisions performed
after pure RS was found on initial CNB, and the number
of upgrades to carcinoma, both invasive and non-invasive,
and the type of carcinoma [DCIS or Invasive Breast Cancer
(IBC) which includes IDC and invasive lobular carcinoma
(ILC)] were recorded. An overall upgrade rate among the
studies was calculated. From our literature review, there
were a total of 37 out of 1085 cases of upgrades to carcinoma yielding an overall upgrade rate of 3.4%, which is
consistent with our institutional study.
Of the 15 other studies, four studies: Nassar et al. [18],
Mooney et al. [3], Rageth et al. [2], and Ferreira et al. [19]
yielded comparatively high upgrade rates (10.5, 16.0, 10.9,
13.5%, respectively, average upgrade rate 12.6%, 25 of
198 total patients) to malignancy compared to the other
11 studies (average upgrade 1.4%, 12 of 887 patients).
The exclusion criteria for first three studies were similar
in that patients with any atypia observed with RS on CNB
were excluded. Nassar et al. also excluded cases in which
the pathological diagnosis on the CNB was RS (≤ 1.0 cm)
or Complex Sclerosing Lesions (CSL) (> 1.0 cm) associated with atypical epithelial hyperplasia, lobular neoplasia, DCIS, and malignancy [18]. Mooney et al. excluded
RS associated with any type of epithelial atypia and cases
with known synchronous ipsilateral breast cancer [3]. Ferreria et al. excluded patients with a simultaneous breast

Table 5  Literature review
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malignancy (invasive or in situ breast cancer) and also
patients with a follow-up interval less than 12 months if
surgery was not performed after an image-guided CNB
[19]. Rageth et al. did not specifically list exclusion criteria in their publication [2]. Whereas the exclusion criteria
of the remaining 11 studies were all patients with concurrent ipsilateral breast cancer, coexisting atypia present
with RS in core specimen, excision at an outside institution, lost to follow up after benign pathology results,
and/or radiology–pathology discordance [20–30]. Thus,
variability in exclusion criteria may account for the higher
upgrade rates in some studies compared with others.

Discussion
It has been recommended that patients with RS detected
on image-guided CNB undergo surgical excision due to
the high upgrade rate observed in surgical specimens. In
our institutional series, we observed a low upgrade rate
of 3.6% for all patients who had a surgical excision after
CNB. Consistent with our finding, review of literature
published between years 2014 and 2018, yielded an overall
upgrade rate of 3.4%. Moreover, with a mean follow-up of
32.3 months, none of the other 120 patients in our series
developed IBC or DCIS in the area of the RS biopsy, with
or without excision.
A distinction needs to be made between RS detected
mammographically versus that detected histopathologically. RS detected mammographically have been reported
to be associated with early breast cancer, DCIS, and ADH

Year

Author

Upgrade
rate (%)

Excision (n)

Upgrade (n)

DCIS (n)

IBC (n)

2014
2015
2015
2015
2016
2016
2016
2016
2016
2016
2016
2016
2016
2017
2017
2018
Total

Miller et al. [24]
Matrai et al. [25]
Conlon et al. [21]
Nassar et al. [18]
Leong et al. [20]
Donaldson et al. [26]
Mooney et al. [3]
Kalife et al. [27]
Park et al. [28]
Li et al. [22]
Hou et al. [29]
Kim et al. [23]
Rageth et al. [2]
Nakhlis et al. [30]
Ferreira et al. [19]
Chou et al.

2.0
0.0
0.0
10.5
0.6
0.0
16.0
2.4
0.0
0.9
0.0
1.6
10.9
8.8
13.5
3.6
3.4

102
77
47
38
161
37
25
41
10
220
40
63
46
34
89
55
1085

2
0
0
4
1
0
4
1
0
2
0
1
5
3
12
2
37

1
0
0
2
1
0
3
1
0
1
0
1
4
2
7
0
23

1
0
0
2
0
0
1
0
0
1
0
0
1
1
5
2
14
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in up to half of women and thus should be sampled by
image-guided biopsy [4]. This is in contrast to RS detected
on core biopsies for abnormal mammographic findings.
RS found histopathologically on CNB have been associated with multiple mammographic entities including
masses, architectural distortion, calcifications, asymmetries, and may or may not correspond to RS detected
mammographically [2, 8]. Our data and data reported in
the literature indicate that there is no single radiographic
or mammographic finding associated with upgrade of
RS found on CNB to a cancer or which identifies those
RS which need to be excised versus those which can be
safely monitored [31, 32]. For example, in our series, the
mammographic findings which triggered the initial CNB
in the two cases upgraded to cancer were a mass and an
architectural distortion. In other reported series, upgrade
to cancers was associated with architectural distortions,
larger masses (≥ 1 cm), calcifications, and older age [3,
22, 23]. Thus, the management of RS detected on CNB
has ranged from surgical excision [33] or mammographic
surveillance [4].
Part of the current RS management dilemma is the high
variability of upgrade rates of pure RS among different
institutional studies. In our review of 16 studies, including
our data, published between 2014 and 2018, we calculated
an overall upgrade rate to cancer of approximately 3.4% in
patients diagnosed with RS on image-guided CNB with a
range of 0–16.0%. While no single factor could account for
the wide range in upgrade rate in the studies, several factors, such as year of the biopsy, biopsy device, and patient
population, may affect the variability upgrade rate in the
reported studies.
We found that more contemporary studies, with data
from 2000 to 2017, reported very low upgrade rates.
Kim et al. reported an upgrade rate on excision of 1.6%
(1 out of 63 patients) [23]. Similar to our study, 25% of
their patients did not undergo surgical excision and with
a median follow-up of 26 months; none of the patients
developed cancer. Leong et al. found an upgrade rate < 1%
in 161 patients with pure RS [20].
The type of biopsy device on upgrade rate has been
examined to determine whether larger core biopsy gauge
or VAB led to an improved false-negative rate for cancer
detection when radial scar is detected on CNB. If a VAB
showed RS on histology, some believed surveillance to be
sufficient [2]. Three studies reported no upgrade to malignancy if VAB or needle greater than 11 g is used [34–36].
These three studies had a combined patient population of
422, which represents about 22% of the patients in the
studies we reviewed; thus, it is can be reasonably assumed
that RS detected on CNB using large core gauge or VAB
can be safely managed conservatively.
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High variability in upgrade rates may be due to differences in inclusion criteria for each study, which can lead
to case selection bias. For example, in studies reported by
Hou et al. [29] and Li et al. [22], all patients with a history
or family history of breast cancer or atypical proliferative
lesions defined as flat epithelial atypia, atypical ductal
hyperplasia, and lobular neoplasia were excluded. As a
result, Hou et al. [29] and Li et al. [22] observed upgrade
rates of 0.0 and 0.9%, respectively.
Variability can also be attributed to the method some
studies chose to characterize RS. Matrai et al. [25] limited
the study population to those RS with that were 0.5 cm or
smaller. However, studies have included patients with RS
ranging from 0.1 to 5 cm [25, 32, 35, 37].
Upgrade from RS to cancers may be incidental findings as has previously been discussed [20–22] and is
likely the case with the two patients in our series. Most
cancers detected on surgical excision for RS on CNB are
low grade and prognostically favorable [16, 31, 38, 39].
In the literature review, 2.1% of patients had DCIS after
excision for RS on CNB and 1.3% had IBC. Thus, these
indolent cancers may have become apparent with close
clinical follow-up and later detection would likely have
little effect on overall patient outcome.
In our institutional study, none (0/26) of the RS with
atypia on CNB were upgraded to malignancy upon surgical excision. This is in contrast to the higher number of
upgrades to malignancy upon surgical excision with initial
diagnosis of RS with associated atypia on CNB seen in
other studies [3, 4, 20, 26, 35]. In two studies of RS and
HRL on CNB, Leong et al. [20] found 6 of 54 (11%) cases
of surgical pathology upgrades and Donaldson et al. [26]
found 7 of 21 (33%) cases of upgrades to malignancy. Our
low rate of upgrade in RS with HRL on CNB could be due
to the low patient number, improved imaging, and biopsy
devices.
Several studies published between 2007 and 2012 suggested surgical excision of pure RS on CNB, due to the association with malignancy [32, 37] and false-negative biopsy
in RS [33]. Nizri et al. examined the practice management
of RS detected on image-guided biopsies [40] and found
that 40% of breast surgeons recommended selective excision
based on imaging and pathological correlation, size of the
lesion, and the presence of atypia on the pathology and 57%
of the respondents recommended routine excision.
Considering the advancements in breast imaging, pathology, and multidisciplinary approaches to current RS management, along with our findings in this study, we believe
that surgical excision is not necessary for RS without associated atypia on core needle biopsies. Instead follow-up imaging, a less invasive approach, appears appropriate given the
low upgrade rates to malignancy and the low-grade cancers
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detected. This would save 97 patients a surgical procedure to
detect 3 low-grade cancers, 2 of which are likely to be DCIS.
There are limitations to our study including single institution, retrospective patient population, and high volume practice with dedicated mammographers and breast pathologists,
which may not be available at every institution. We were also
unable to reliably obtain information on related family history of cancer. Additionally, as with any retrospective study,
we are subject to impose our biases on our sample population and are also limited to the cases seen at our institution.

Conclusion
We have found a low upgrade rate to cancer in RS and RS
with HRL detected on image-guided CNB. Our results are
consistent with other large institutional studies. Given the
low upgrade rate to malignancy, we propose that upon finding small, incidental RS on CNB, subsequent surgical excision is not necessary unless there are other reasons for excision such as the presence of HRL or discordance with the
mammographic findings. Instead, close clinical follow-up or
routine imaging, a less invasive approach, is recommended.
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